COMPANY
Board of Directors
COMPANY
Board of
Directors
Improving the quality of healthcare worldwide
Committed to providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.
Committed to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.
HARDWICK SIMMONS, MBA
Hardwick ‘Wick’ Simmons retired as the Chairman and CEO of The Nasdaq Stock Market, Inc. in May of 2003. Prior to Nasdaq, he served as President and CEO of Prudential Securities Inc., a major investment management and securities brokerage firm.
Simmons is a former chairman of the Securities Industry Association, a former director of the Chicago Board Options Exchange and a former president of the New York Bond Club. He is currently a director of Lionsgate Entertainment Corp., president of Stonetex Oil Corp., and a trustee of Woods Hole Oceanographic Institution. He is a graduate of Harvard College and Harvard Business School and served in the U.S. Marine Corps Reserve from 1960 until 1966.
MITCHELL KRONENBERG, PH.D.
Mitchell Kronenberg received a B.A. from Columbia University, a Ph.D. from the California Institute of Technology, and served on the faculty of the UCLA School of Medicine from 1986-1997. He joined the La Jolla Institute for Immunology in 1997, and is currently a Professor, the President Emeritus and a member of the institute’s Board of Directors. The Institute has grown in accomplishment and reputation under his leadership.
Dr. Kronenberg’s research interests include natural killer T cells, other innate lymphocytes such as MAIT cells and ILC, regulation of mucosal immunology and the microbiome and pathogenesis of inflammatory bowel disease. He has co-authored more than 350 publications, and is a fellow of the American Association for the Advancement of Science (AAAS), a Distinguished Fellow of the American Association of Immunologists, recipient of an NIH MERIT award and is an Institute for Scientific Information (ISI) Highly Cited Scientist. In 2016, he was named the most admired CEO (large nonprofit organization category) by the San Diego Business Journal. He is an advisor to a number of organizations including service as a member of the Board of Scientific Counselors for Basic Science, National Cancer Institute and he has been involved with Invivoscribe since its founding.
JEFFREY EDWARD MILLER, PH.D.
Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® – coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.
Prior to starting Invivoscribe, Dr. Miller had more than twenty years of combined experience in protein biochemistry, cellular and molecular immunology, cardiac physiology, virology, and molecular biology, experience he had developed working in laboratories at the Medical School, Department of Chemistry, Molecular Biology Institute at UCLA, while earning his Ph.D. at UCSB, and as a postdoctoral scientist at Applied Molecular Evolution. He also spent several years at Quest Diagnostics Nichols Institute, setting up the molecular oncology laboratory and developing and launching PCR-based molecular assays for infectious disease and hematopathology.
Dr. Miller has a number of patents, peer-reviewed publications, and he has contributed to chapters in textbooks. He has been a member of the Association for Molecular Pathology for more than two decades, and is a member of ASH, EHA, and ASCO.
STEPHEN WILSON, PH.D.
Dr. Wilson is a biomedical research executive with more than two decades of experience in basic and translational immunology.
He received his B.S.A. and Ph.D. from the University of Arizona, and serves as the Chief Executive Officer of Foundation Immune Engineering’s Botnar Institute.
JAMES ISAACS, JR., JD
James B. Isaacs, Jr. has practiced law since 1983. He currently serves as Licensing and Contracts Counsel at Invivoscribe.
Jim attended Stanford University and Yale Law School, then began his career at the Los Angeles law firm of O’Melveny & Myers. As a trial lawyer and later in-house counsel with a focus on intellectual property disputes, Jim has successfully defended myriad businesses and individuals; in plaintiffs’ actions he has obtained and collected multi-million dollar judgments in the United States and abroad. As a businessman and co-founder of Invivoscribe, Jim has been active in the legal and commercial affairs of the company since 1995.
GARY CLOUSE, JD
